跳至主要内容
临床试验/NCT00040131
NCT00040131终止2 期

Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

Merck Sharp & Dohme LLC0 个研究点目标入组 316 人开始时间: 2002年1月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
入组人数
316

研究概览

简要总结

The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Adults weighing up to 125 kg who are undergoing ERCP for any of the following:
  • •Evaluate recurrent abdominal pain;
  • •Evaluate unexplained recurrent pancreatitis;
  • •Evaluate prior post-ERCP pancreatitis;
  • •Treatment of pancreatic disorders;
  • •Treatment of Common Bile Duct Stones (without jaundice)

排除标准

  • •Active (acute) pancreatitis;
  • •Chronic pancreatitis (moderate and severe cases);
  • •ERCP to perform a second procedure on biliary tract;
  • •Patients who previously had pancreatic sphincterotomy;
  • •Known or suspected pancreatic cancer or cancer of Papilla of Vater;
  • •Known or suspected other malignancy;
  • •History of, or current clotting or bleeding problems;
  • •Moderate and severe Anemia;
  • •Low platelet counts

研究者

申办方类型
Industry
责任方
Sponsor

相似试验